Global Hip Osteoarthritis Pain Drug Market Research Report 2021

1 Hip Osteoarthritis Pain Drug Market Overview

• 1.1 Product Overview and Scope of Hip Osteoarthritis Pain Drug
• 1.2 Hip Osteoarthritis Pain Drug Segment by Type
  • 1.2.1 Global Hip Osteoarthritis Pain Drug Sales Growth Rate Comparison by Type (2021-2027)
  • 1.2.2 Oral
  • 1.2.3 Injection
  • 1.2.4 External
• 1.3 Hip Osteoarthritis Pain Drug Segment by Application
  • 1.3.1 Hip Osteoarthritis Pain Drug Sales Comparison by Application: (2021-2027)
  • 1.3.2 Medical Care
  • 1.3.3 Personal Care
• 1.4 Global Hip Osteoarthritis Pain Drug Market Size Estimates and Forecasts
  • 1.4.1 Global Hip Osteoarthritis Pain Drug Revenue 2016-2027
  • 1.4.2 Global Hip Osteoarthritis Pain Drug Sales 2016-2027
  • 1.4.3 Hip Osteoarthritis Pain Drug Market Size by Region: 2016 Versus 2021 Versus 2027

2 Hip Osteoarthritis Pain Drug Market Competition by Manufacturers

• 2.1 Global Hip Osteoarthritis Pain Drug Sales Market Share by Manufacturers (2016-2021)
• 2.2 Global Hip Osteoarthritis Pain Drug Revenue Market Share by Manufacturers (2016-2021)
• 2.3 Global Hip Osteoarthritis Pain Drug Average Price by Manufacturers (2016-2021)
• 2.4 Manufacturers Hip Osteoarthritis Pain Drug Manufacturing Sites, Area Served, Product Type
• 2.5 Hip Osteoarthritis Pain Drug Market Competitive Situation and Trends
  • 2.5.1 Hip Osteoarthritis Pain Drug Market Concentration Rate
  • 2.5.2 The Global Top 5 and Top 10 Largest Hip Osteoarthritis Pain Drug Players Market Share by Revenue
  • 2.5.3 Global Hip Osteoarthritis Pain Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Hip Osteoarthritis Pain Drug Retrospective Market Scenario by Region

• 3.1 Global Hip Osteoarthritis Pain Drug Retrospective Market Scenario in Revenue by Region: 2016-2021
• 3.2 Global Hip Osteoarthritis Pain Drug Retrospective Market Scenario in Sales by Region: 2016-2021
• 3.3 North America Hip Osteoarthritis Pain Drug Market Facts & Figures by Country
  • 3.3.1 North America Hip Osteoarthritis Pain Drug Sales by Country
  • 3.3.2 North America Hip Osteoarthritis Pain Drug Revenue by Country
  • 3.3.3 U.S.
  • 3.3.4 Canada
• 3.4 Europe Hip Osteoarthritis Pain Drug Market Facts & Figures by Country
  • 3.4.1 Europe Hip Osteoarthritis Pain Drug Sales by Country
  • 3.4.2 Europe Hip Osteoarthritis Pain Drug Revenue by Country
  • 3.4.3 Germany
  • 3.4.4 France
  • 3.4.5 U.K.
  • 3.4.6 Italy
  • 3.4.7 Russia
• 3.5 Asia Pacific Hip Osteoarthritis Pain Drug Market Facts & Figures by Region
  • 3.5.1 Asia Pacific Hip Osteoarthritis Pain Drug Sales by Region
  • 3.5.2 Asia Pacific Hip Osteoarthritis Pain Drug Revenue by Region
  • 3.5.3 China
  • 3.5.4 Japan
  • 3.5.5 South Korea
  • 3.5.6 India
  • 3.5.7 Australia
  • 3.5.8 Taiwan
  • 3.5.9 Indonesia
  • 3.5.10 Thailand
  • 3.5.11 Malaysia
  • 3.5.12 Philippines
  • 3.5.13 Vietnam
• 3.6 Latin America Hip Osteoarthritis Pain Drug Market Facts & Figures by Country
  • 3.6.1 Latin America Hip Osteoarthritis Pain Drug Sales by Country
  • 3.6.2 Latin America Hip Osteoarthritis Pain Drug Revenue by Country
  • 3.6.3 Mexico
  • 3.6.4 Brazil
  • 3.6.5 Argentina
• 3.7 Middle East and Africa Hip Osteoarthritis Pain Drug Market Facts & Figures by Country
  • 3.7.1 Middle East and Africa Hip Osteoarthritis Pain Drug Sales by Country
  • 3.7.2 Middle East and Africa Hip Osteoarthritis Pain Drug Revenue by Country
  • 3.7.3 Turkey
  • 3.7.4 Saudi Arabia
  • 3.7.5 UAE

4 Global Hip Osteoarthritis Pain Drug Historic Market Analysis by Type

• 4.1 Global Hip Osteoarthritis Pain Drug Sales Market Share by Type (2016-2021)
• 4.2 Global Hip Osteoarthritis Pain Drug Revenue Market Share by Type (2016-2021)
• 4.3 Global Hip Osteoarthritis Pain Drug Price by Type (2016-2021)

5 Global Hip Osteoarthritis Pain Drug Historic Market Analysis by Application

• 5.1 Global Hip Osteoarthritis Pain Drug Sales Market Share by Application (2016-2021)
• 5.2 Global Hip Osteoarthritis Pain Drug Revenue Market Share by Application (2016-2021)
• 5.3 Global Hip Osteoarthritis Pain Drug Price by Application (2016-2021)

6 Key Companies Profiled

• 6.1 Pfizer
  • 6.1.1 Pfizer Corporation Information
  • 6.1.2 Pfizer Description and Business Overview
  • 6.1.3 Pfizer Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2016-2021)
  • 6.1.4 Pfizer Product Portfolio
  • 6.1.5 Pfizer Recent Developments/Updates
• 6.2 Johnson and Johnson
  • 6.2.1 Johnson and Johnson Corporation Information
  • 6.2.2 Johnson and Johnson Description and Business Overview
  • 6.2.3 Johnson and Johnson Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2016-2021)
  • 6.2.4 Johnson and Johnson Product Portfolio
  • 6.2.5 Johnson and Johnson Recent Developments/Updates
• 6.3 GlaxoSmithKline
  • 6.3.1 GlaxoSmithKline Corporation Information
  • 6.3.2 GlaxoSmithKline Description and Business Overview
  • 6.3.3 GlaxoSmithKline Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2016-2021)
  • 6.3.4 GlaxoSmithKline Product Portfolio
  • 6.3.5 GlaxoSmithKline Recent Developments/Updates
• 6.4 Bayer
  • 6.4.1 Bayer Corporation Information
  • 6.4.2 Bayer Description and Business Overview
  • 6.4.3 Bayer Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2016-2021)
  • 6.4.4 Bayer Product Portfolio
  • 6.4.5 Bayer Recent Developments/Updates
• 6.5 Eli Lilly
  • 6.5.1 Eli Lilly Corporation Information
  • 6.5.2 Eli Lilly Description and Business Overview
  • 6.5.3 Eli Lilly Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2016-2021)
  • 6.5.4 Eli Lilly Product Portfolio
  • 6.5.5 Eli Lilly Recent Developments/Updates
• 6.6 Novartis
  • 6.6.1 Novartis Corporation Information
  • 6.6.2 Novartis Description and Business Overview
  • 6.6.3 Novartis Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2016-2021)
  • 6.6.4 Novartis Product Portfolio
  • 6.6.5 Novartis Recent Developments/Updates
• 6.7 Sanofi
  • 6.6.1 Sanofi Corporation Information
  • 6.6.2 Sanofi Description and Business Overview
  • 6.6.3 Sanofi Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2016-2021)
  • 6.4.4 Sanofi Product Portfolio
  • 6.7.5 Sanofi Recent Developments/Updates
• 6.8 Horizon Pharma
  • 6.8.1 Horizon Pharma Corporation Information
  • 6.8.2 Horizon Pharma Description and Business Overview
  • 6.8.3 Horizon Pharma Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2016-2021)
  • 6.8.4 Horizon Pharma Product Portfolio
  • 6.8.5 Horizon Pharma Recent Developments/Updates
• 6.9 Abbott
  • 6.9.1 Abbott Corporation Information
  • 6.9.2 Abbott Description and Business Overview
  • 6.9.3 Abbott Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2016-2021)
  • 6.9.4 Abbott Product Portfolio
  • 6.9.5 Abbott Recent Developments/Updates
• 6.10 Mylan
  • 6.10.1 Mylan Corporation Information
  • 6.10.2 Mylan Description and Business Overview
  • 6.10.3 Mylan Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2016-2021)
  • 6.10.4 Mylan Product Portfolio
  • 6.10.5 Mylan Recent Developments/Updates
• 6.11 Daiichi Sankyo
  • 6.11.1 Daiichi Sankyo Corporation Information
  • 6.11.2 Daiichi Sankyo Hip Osteoarthritis Pain Drug Description and Business Overview
  • 6.11.3 Daiichi Sankyo Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2016-2021)
  • 6.11.4 Daiichi Sankyo Product Portfolio
  • 6.11.5 Daiichi Sankyo Recent Developments/Updates
• 6.12 TEVA
  • 6.12.1 TEVA Corporation Information
  • 6.12.2 TEVA Hip Osteoarthritis Pain Drug Description and Business Overview
  • 6.12.3 TEVA Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2016-2021)
  • 6.12.4 TEVA Product Portfolio
  • 6.12.5 TEVA Recent Developments/Updates
• 6.13 Almatica Pharma
  • 6.13.1 Almatica Pharma Corporation Information
  • 6.13.2 Almatica Pharma Hip Osteoarthritis Pain Drug Description and Business Overview
  • 6.13.3 Almatica Pharma Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2016-2021)
  • 6.13.4 Almatica Pharma Product Portfolio
  • 6.13.5 Almatica Pharma Recent Developments/Updates
• 6.14 Astellas Pharma
  • 6.14.1 Astellas Pharma Corporation Information
  • 6.14.2 Astellas Pharma Hip Osteoarthritis Pain Drug Description and Business Overview
  • 6.14.3 Astellas Pharma Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2016-2021)
  • 6.14.4 Astellas Pharma Product Portfolio
  • 6.14.5 Astellas Pharma Recent Developments/Updates
• 6.15 Tide Pharmaceutical
  • 6.15.1 Tide Pharmaceutical Corporation Information
  • 6.15.2 Tide Pharmaceutical Hip Osteoarthritis Pain Drug Description and Business Overview
  • 6.15.3 Tide Pharmaceutical Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2016-2021)
  • 6.15.4 Tide Pharmaceutical Product Portfolio
  • 6.15.5 Tide Pharmaceutical Recent Developments/Updates
• 6.16 Iroko Pharmaceuticals
  • 6.16.1 Iroko Pharmaceuticals Corporation Information
  • 6.16.2 Iroko Pharmaceuticals Hip Osteoarthritis Pain Drug Description and Business Overview
  • 6.16.3 Iroko Pharmaceuticals Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2016-2021)
  • 6.16.4 Iroko Pharmaceuticals Product Portfolio
  • 6.16.5 Iroko Pharmaceuticals Recent Developments/Updates
• 6.17 Hengrui Pharmaceutical
  • 6.17.1 Hengrui Pharmaceutical Corporation Information
  • 6.17.2 Hengrui Pharmaceutical Hip Osteoarthritis Pain Drug Description and Business Overview
  • 6.17.3 Hengrui Pharmaceutical Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2016-2021)
  • 6.17.4 Hengrui Pharmaceutical Product Portfolio
  • 6.17.5 Hengrui Pharmaceutical Recent Developments/Updates
• 6.18 Abiogen Pharma
  • 6.18.1 Abiogen Pharma Corporation Information
  • 6.18.2 Abiogen Pharma Hip Osteoarthritis Pain Drug Description and Business Overview
  • 6.18.3 Abiogen Pharma Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2016-2021)
  • 6.18.4 Abiogen Pharma Product Portfolio
  • 6.18.5 Abiogen Pharma Recent Developments/Updates

7 Hip Osteoarthritis Pain Drug Manufacturing Cost Analysis

• 7.1 Hip Osteoarthritis Pain Drug Key Raw Materials Analysis
  • 7.1.1 Key Raw Materials
  • 7.1.2 Key Suppliers of Raw Materials
• 7.2 Proportion of Manufacturing Cost Structure
• 7.3 Manufacturing Process Analysis of Hip Osteoarthritis Pain Drug
• 7.4 Hip Osteoarthritis Pain Drug Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

• 8.1 Marketing Channel
• 8.2 Hip Osteoarthritis Pain Drug Distributors List
• 8.3 Hip Osteoarthritis Pain Drug Customers

9 Hip Osteoarthritis Pain Drug Market Dynamics

• 9.1 Hip Osteoarthritis Pain Drug Industry Trends
• 9.2 Hip Osteoarthritis Pain Drug Growth Drivers
• 9.3 Hip Osteoarthritis Pain Drug Market Challenges
• 9.4 Hip Osteoarthritis Pain Drug Market Restraints

10 Global Market Forecast

• 10.1 Hip Osteoarthritis Pain Drug Market Estimates and Projections by Type
  • 10.1.1 Global Forecasted Sales of Hip Osteoarthritis Pain Drug by Type (2022-2027)
  • 10.1.2 Global Forecasted Revenue of Hip Osteoarthritis Pain Drug by Type (2022-2027)
• 10.2 Hip Osteoarthritis Pain Drug Market Estimates and Projections by Application
  • 10.2.1 Global Forecasted Sales of Hip Osteoarthritis Pain Drug by Application (2022-2027)
  • 10.2.2 Global Forecasted Revenue of Hip Osteoarthritis Pain Drug by Application (2022-2027)
• 10.3 Hip Osteoarthritis Pain Drug Market Estimates and Projections by Region
  • 10.3.1 Global Forecasted Sales of Hip Osteoarthritis Pain Drug by Region (2022-2027)
  • 10.3.2 Global Forecasted Revenue of Hip Osteoarthritis Pain Drug by Region (2022-2027)

11 Research Finding and Conclusion

12 Methodology and Data Source

• 12.1 Methodology/Research Approach
  • 12.1.1 Research Programs/Design
  • 12.1.2 Market Size Estimation
  • 12.1.3 Market Breakdown and Data Triangulation
• 12.2 Data Source
  • 12.2.1 Secondary Sources
  • 12.2.2 Primary Sources
• 12.3 Author List